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Human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPC)
is a distinct clinical entity within the head and neck cancers, with a unique epidemiology
and, in general, a favorable prognosis. Because of this favorable prognosis, researchers
have considered de-intensifying the current standard treatment of HPV+ OPC in order
to reduce acute and late treatment related toxicity without compromising outcome.
Current ongoing trials can be divided in three main categories: de-intensification of
the chemotherapy by replacing concomitant platinum-based chemotherapy with the
EGFR-inhibitor cetuximab, or de-intensification of the radiation dose of either the primary
radiotherapy of selected, good-responding patients after induction chemotherapy or of
the adjuvant radiotherapy based on pathology features after primary surgery. Despite
the good prognosis of the majority of HPV+ OPC patients, a proportion of them still
have poor prognosis. This unmet need has led clinical research on new treatment
strategies focused on influencing the unique micro-environment of HPV+ OPC with for
example immunotherapy. This article summarizes the current understanding regarding
the optimal treatment of non-metastatic HPV+OPC. Ongoing and published clinical trials
regarding de-intensification strategies, immunotherapy and proton therapy are described
focusing on the rationale and underlying evidence of these emerging treatment strategies.
Nevertheless, until the results of the ongoing trials are known, the treatment of HPV+
OPC in clinical practice should remain identical to the treatment of HPV negative OPC.
Keywords: head and neck cancer, oropharyngeal cancer, human papillomavirus, HPV, de-intensification trials
INTRODUCTION
Oropharyngeal squamous cell carcinomas (OPC) are tumors located in the soft palate, the
pharyngeal wall, the tonsils or the base of tongue, the latter two being the preferred location of
Human Papillomavirus related (HPV+) OPC. The incidence of OPC is increasing in the developed
countries, chiefly attributed to the epidemic increase in incidence of HPV+ OPC (1, 2).
HPV+OPC has a better prognosis than tobacco and alcohol related (HPV–) OPC. They should,
therefore, be considered as two distinct clinical entities. This is reflected in the new AJCC/UICC
TNM 8th edition (8th Ed) staging system with a different classification for HPV+ and HPV– OPC
(3). The new clinical (c) TNM 8th Ed for HPV+ OPC contains adjustments in both T- and N-
classification. cT-classification remained unchanged except for the disappearance of the distinction
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TABLE 1 | Differences in clinical group staging between the 7th and 8th edition
AJCC/UICC TNM classification system (cTNM) for Human Papillomavirus related
oropharyngeal squamous cell carcinoma.
Stage TNM 7th edition cTNM 8th edition
I T1N0 T1T2-N0N1
II T2N0 T3-N0N2; T1T2-N2
III T3-N0N1; T1T2-N1 T4Nany; TxN3
IV IVa: T4a-N0N2c; T1T3-N0N2c
IVb: T4bNany; Tany N3
IVc: TanyNanyM1
TanyNanyM1
of the T4-classification in T4a and T4b. The cN-classification,
on the other hand, has changed extensively: N0 is the absence
of malignant lymph nodes, N1 is reserved for one or more
ipsilateral lymph nodes smaller than 6 cm, N2 is the presence
of contralateral or bilateral lymph nodes smaller than 6 cm
while N3 is one or more lymph nodes larger than 6 cm. The
presence of extranodal extension is not a classification parameter
in contrast to the TNM 8th Ed for HPV– OPC. Table 1 shows
the differences in the clinical group staging between the 7th and
8th Ed for HPV+ OPC. In the pathological (p) TNM 8th Ed
classification, pT-classification is the same as cT-classification
while pN-classification is exclusively defined by the number of
pathological lymph nodes.
Although the prognosis of HPV+ OPC is better than that
of HPV– OPC, currently, the treatment of these two entities
is identical (4). Nevertheless, researchers have attempted to de-
intensify the treatment of HPV+ OPC to minimize treatment
related toxicity without compromising the oncologic outcome.
On the other hand, a part of the HPV+ OPC still have
poor prognosis directing clinical research to new treatment
strategies focusing on influencing the uniquemicro-environment
of HPV+ OPC with for example immunotherapy. In this
paper, we will discuss the current treatment of HPV+ OPC,
the ongoing or completed de-intensification trials, their results
and underlying rationale. Last, we will briefly describe the
potential place of immunotherapy and proton therapy in HPV+
OPC. The review was based on a literature search of PubMed
with the Medical Subject Heading term “oropharyngeal cancer”
AND “human papillomavirus” combined with the key words
“radiotherapy,” “toxicity,” “de-escalation,” “de-intensification,”
and “dose reduction.” The PubMed search was combined with
back tracking based on published reference lists.
CURRENT TREATMENT
The treatment of HPV+ OPC depends on patient related
characteristics in combination with tumor location, tumor
extension, lymph node status and relies, as a result, on accurate
staging. The staging and treatment of HPV+ OPC and more
generally of head and neck squamous cell carcinoma (HNSCC)
can generally be divided in two categories, early vs. locally
advanced disease.
Early disease, (T1 or T2 tumor with maximum one ipsilateral
malignant lymph node smaller than 3 cm), is treated with a
single modality treatment, surgery or radiotherapy (RT). Locally
advanced disease is treated with combined modality treatment
consisting of either RT with concomitant chemotherapy (CRT)
or cetuximab or of surgery followed by adjuvant RT or
by adjuvant CRT in case of positive resection margins or
extranodal extension (ENE) (5–9). Treatment decisions are made
by a multidisciplinary setting, and take into account patient
characteristics and the anticipated functional outcomes after
surgery.
The added value of concomitant platinum-based
chemotherapy in addition of primary RT treatment of locally
advanced disease has been demonstrated in a large meta-
analysis of 9615 subjects (5). Trials with addition of induction
chemotherapy (ICT) to CRT have failed to demonstrate any
benefit in overall survival or progression free survival and
ICT is therefore not considered standard-of-care (5, 10, 11).
Alternatively, the addition of cetuximab, a chimeric epidermal
growth factor receptor (EGFR)-inhibitor, in combination with
primary radiotherapy has shown improved overall survival,
but only in one study including 424 patients (6). Since the
two different concomitant systemic therapies, platinum-based
chemotherapy and cetuximab, in addition to RT were never
compared head-to-head in a randomized controlled trial and
the evidence for the use of platinum-based chemotherapy is
based on a larger dataset, RT plus concomitant platinum-based
chemotherapy is favored, while cetuximab can be given to
patients with contra-indications for platinum derivates.
CHANGES IN PRIMARY
(CHEMO)RADIOTHERAPY
Radiotherapy induces treatment related toxicities correlated to
the RT dose delivered to normal tissues (12, 13). Moreover,
concomitant systemic treatment significantly increases the acute
and late toxicity (6, 14). This toxicity strongly influences
the quality of life of cancer patients (15). The avoidance
or diminution of treatment related toxicity becomes more
prominent in patients with a good long-term prognosis, such
as in HPV+ OPC. For this reason, researchers have attempted
to reduce toxicity by changing or leaving out the concomitant
therapy or by reducing the RT dose. First, we will discuss the
changes in the concomitant systemic therapy. Next, we will
discuss the trials with reduced RT dose and with RT dose
adaptation after ICT.
Replacement of Cisplatin by Cetuximab
Cisplatin increases the acute and late toxicity with severe
mucositis, dermatitis, dysphagia and potential life threatening
neutropenic fever, while the use of cetuximab is classically only
associated with the typical acneiform rash, hypomagnesemia and
infusion reaction (5–7, 14, 16). In addition, a subgroup analysis of
the Bonner trial, although underpowered and unplanned, showed
that especially younger patients with oropharyngeal cancer, early
T stage and advanced N-stage had an improved overall survival
with cetuximab-RT compared to RT only (6). The hypothesis
rose that these patients for whom cetuximab treatment would
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be the most beneficial, were HPV+ OPC, typically presenting
at younger age with small primary tumors and multiple lymph
nodes.
Several running de-intensification trials hypothesize that
treatment with cetuximab-RT is non-inferior to CRT for HPV+
OPC and that cetuximab is associated with a more favorable
treatment related toxicity profile and better long-term quality of
life. The De-ESCALaTE trial (NCT01874171) and TROG 12.01
trial (NCT01855451) compare the toxicity of both treatments,
whereas the largest trial, the RTOG 1016 (NCT01302834),
including around 1,000 patients, is currently the only randomized
controlled trial with oncologic outcome as primary endpoint
(Table 2). Although this treatment approach is promising, the
efficacy of cetuximab in HPV+ OPC is controversial. Several
researchers are convinced that only HPV– OPC can benefit from
cetuximab based on several studies demonstrating an inverse
relationship between EGFR expression and detection of HPV.
In addition, the Cancer Genome Atlas group, examining at the
cumulative effect of various mechanisms of biological alterations
in HNSCC, suggested EGFR as a relevant oncogenic target
but only in HPV– OPC (17–20). In contrast, Rosenthal et al.
conducted a retrospective subset analysis of the IMCL-9815 trial
of Bonner et al. focusing on the potential impact of p16 status
(a surrogate marker of HPV positivity) on the outcome of 182
OPC patients (6, 21). They showed benefit for cetuximab on
locoregional control and overall survival in both p16+ and p16–
subgroup. Although their data suggested a more pronounced
gain from cetuximab in the p16+ subgroup, no significant
interaction between treatment group and p16 status was shown,
confirming p16 status as a prognostic biomarker, though not
a predictive biomarker (21). Interestingly, EGFR expression is
also a prognostic biomarker but not predictive for the efficacy of
cetuximab (22). Many now believe that the antitumoral activity
of cetuximab is mainly an immunologic response on the non-
human part of the antibody by potentiating the cytotoxic T-
cell antitumor immune response, rather than through EGFR-
inhibition (23, 24). This could explain why trials with fully human
EGFR-inhibitors, like panitumumab, have failed to demonstrate
any survival benefit compared to or in addition to platinum-
based chemotherapy (25–28). HPV+ OPC could potentially
benefit more of the enhanced immune response by cetuximab
than HPV– OPC since HPV+ OPC contains elevated T- and
B-lymphocyte infiltration and expresses viral proteins (24). To
conclude, despite considerable research devoted to this topic,
many questions with respect to the use of EGFR-inhibitors and
in particular of cetuximab remain unanswered until now. Results
of the afore-mentioned trials will hopefully bring clarification.
Interestingly, an interim analysis of the RTOG 1016 trial found
that treatment with RT and cetuximab is associated with worse
overall and progression-free survival compared to the current
standard treatment with RT and cisplatin (29).
Beside treatment efficacy, we must consider other potential
pitfalls of these de-intensification trials. The TROG 12.01 trial
compares the acute toxicity of radiotherapy (70Gy) plus weekly
cisplatin with radiotherapy (70Gy) plus weekly cetuximab.
A recent systematic review and meta-analysis of Szturz et
al. compared two different cisplatin schedules, the traditional
3 weekly high-dose vs. the weekly low-dose regimen, in
combination with altered radiotherapy and demonstrated less
complications in terms of severe acute mucositis, constipation,
toxic deaths and severe late subcutaneous fibrosis in patients
receiving the 3 weekly high-dose cisplatin regimen. In addition,
the overall survival and compliance differed significantly in
favor of the 3-weekly schedule (30). The potential observed
toxicity differences in the TROG 12.01 could therefore be not
representative of a 3-weekly cisplatin regimen. Furthermore, the
toxicity results of the TROG12.01 trial will be difficult to compare
with the results of the De-ESCALaTE trial, examining the toxicity
of radiotherapy (70Gy) plus 3-weekly cisplatin vs. radiotherapy
(70Gy) plus weekly cetuximab, as their control arms may have a
different toxicity profile.
Another concern is the wide inclusion criteria of the RTOG
1016 trial, including T1T2-N2aN3 and T3T4-Nany (TNM 7th
Ed) and the influence on the distant metastasis rate. Although
the MACH-NC group did not demonstrate an influence of
concomitant chemotherapy on distant metastasis, O’Sullivan et
al. have shown that the benefit of cisplatin on distant metastasis
in N0N2a disease is limited, while in N2cN3 disease and in
heavy smokers with N2b-disease (7th Ed) chemotherapy has
a significant effect (5, 31). In contrast, the Bonner trial has
shown improvement by cetuximab of the locoregional control,
progression free survival and overall survival but has failed to
show an effect on distant metastasis (6). The replacement of
cisplatin by cetuximab in N2b heavy smokers or N2c-N3 disease
could have detrimental effects on the development of distant
metastasis and by consequence on the overall survival. It will
be important to keep in mind the O’Sullivan et al. study when
interpreting the results of the RTOG 1016 trial.
Lastly, the study design of the RTOG 1016 trial, namely a non-
inferiority trial, holds some disadvantages. In non-inferiority
trials, minor differences are accepted and demonstration of non-
inferiority is therefore not the demonstration of equivalence.
A sufficient number of deaths must happen to provide enough
statistical power for analysis otherwise potential inferiority might
not be ruled out due to wide confidence intervals. Before
the start of the trial, the researchers must carefully select the
minimum clinically relevant difference, commonly called delta.
This delta must be substantially smaller than the estimated
benefit of the active treatment, cisplatin, otherwise it could
happen that the new treatment, cetuximab, is not better than
placebo but gets accepted as non-inferior (32, 33). Interestingly,
Brotherston et al. conducted an investigation with questionnaires
assessing patients’ preferences regarding the acceptable delta for
de-intensification cancer treatment. They showed that patients’
primary concern was survival with 35% of the patients unwilling
to risk any drop in survival probability, even if it implied less
treatment related toxicity, and a further 34% of patients willing
to acceptmaximum5% reduction in survival probability (34).We
must therefore be cognizant that the priorities of patients might
be different that those of researchers.
Radiotherapy Dose Reduction
HPV+OPC is believed to be more radiosensitive than the HPV–
OPC and may be cured with doses less than 70Gy (35). A
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TABLE 2 | De-intensification trials replacing cisplatin by cetuximab.
Name study Design Inclusion TNM 7th Inclusion TNM 8th Smoking Primary
endpoint
De-ESCALaTE
NCT01874171
70Gy + 3-weekly
cddp vs.
70Gy + weekly
Cetuximab
T3T4-N0;
T1N1-T4N3
T3T4-N0;
T1N1-T4N3
Exclusion if more than 10
PY and more than one
ipsilateral LN, contralateral
LN or LN > 6 cm
Acute and late
toxicity (2Y)
TROG 12.01
NCT01855451
70Gy + weekly
cddp vs.
70Gy + weekly
Cetuximab
T3-N0N2c;
T1T2-N2aN2c
T3-N0N2;
T1T2-N1N2 (excluding
N1 with only one
ipsilateral LN < 3 cm)
Exclusion if more than 10
PY and more than one
ipsilateral LN or contralateral
LN
Symptom severity:
acute toxicity
RTOG 1016
NCT01302834
70Gy + 3-weekly
cddp vs.
70Gy + weekly
Cetuximab
T1T2-N2aN3;
T3T4-Nany
T1T2-N1N2 (excluding
N1 with only one
ipsilateral LN < 3 cm);
T3T4-Nany
/ Overall survival
NCT01663259 One arm:
70Gy + weekly
cetuximab
T3-N0N2c;
T1T2-N1N2c
T3-N0N2; T1T2-N1N2 <10 PY Recurrence rate
(3Y)
cddp, cisplatin; LN, Lymph nodes; PY, smoking pack years; 2Y,3Y, up to 2 or 3 years after end of treatment.
lower RT dose delivered to the tumor might lead to a lower
dose on the surrounding normal tissue and to less toxicity with
the same good oncologic outcome. This was first investigated
in a prospective, multi-institutional, phase II study in which all
patients were treated with RT at 60Gy at 2Gy per fraction, 5 days
a week with weekly low-dose cisplatin, 30 mg/m² (Table 3). Four
to eight weeks after completion of RT, all patients were evaluated
for clinical complete response (cCR), defined as no measurable
tumor present on physical and radiologic examination, followed
by planned surgical evaluation to asses pathologic complete
response (pCR). In patients who had a cCR at the primary site,
directed biopsies of the primary site were taken while minimally
invasive resection was performed if there was no cCR at the
primary site. All patients who had node-positive disease before
RT had selective nodal dissection. The pCR rate at the primary
site was 86% and in the neck 98% (36). Recently, the long-term
follow-up was published with an observed 3 year cause-specific
survival of 100% and an OS rate of 95% (37). It is, however,
not possible to determine if the planned surgical evaluation
was therapeutic because the clonogenic viability of the residual
foci could not be determined by microscopic examination. CRT
followed by surgery in all patients is probably an overtreatment
and an unnecessary enhancement of toxicity, although in this
trial the patients’ reported long term symptom burden was
low to moderate. Patient selection is opportune and is under
investigation in the follow-up study (NCT02281955). Patients
will receive the same de-intensified CRT regimen, followed by a
12-week post-CRT positron emission tomography/CT to guide
the use of surgery (36–38).
Another research group has de-intensified the treatment even
further by eliminating the concomitant therapy completely in
combination with lowering the RT dose. The NRG HN002 trial
(NCT02254278) randomized patients between RT dose of 60Gy,
one fraction a day for 6 weeks, with or without weekly cisplatin.
Their inclusion criteria are based on the research of O’Sullivan
et al. showing equal effect in terms of distant metastasis of RT,
mostly accelerated regimens, and CRT for N0-N2a and N2b
disease with less than 10 pack years (31). Notably, the RT regimen
of the HN002 trial is significantly different from the regimen
of the trial of O’Sullivan. This NRG HN002 trial is set up with
a conventional fractionation regimen up to 60Gy instead of
the standard RT dose of 70Gy or the accelerated RT regimen
from the study of O’Sullivan et al. meaning this trial consists
of two nonstandard arms. Even more, the time till the primary
endpoint, 2 year progression free survival, might be too short to
measure the effect of leaving out the concomitant therapy. Several
publications have shown that the distantmetastasis rate of HPV+
and HPV– OPC is similar but the timing of onset is different with
the curve of HPV+ OPC continuing to increase for up to 5 years
after treatment in contrast to the rather stable curve of HPV–
OPC beyond 2 years (31, 39).
Dose Adaptation After Induction
Chemotherapy
A meta-analysis of five randomized trials including over 1,000
patients could not show an OS or PFS benefit of induction
chemotherapy (ICT) with docetaxel, cisplatin and 5-FU (TPF)
compared to definitive CRT without induction chemotherapy
in locally advanced HNSCC (10). The Eastern Cooperative
Oncology Group (ECOG) published in 2007 a phase II trial
(E2399) of taxane-based induction chemotherapy followed by
CRT and obtained high organ preservation rate with low toxicity
for OPC (40). Based on these results the ECOG investigated in
a phase II trial, E1308, the further use of ICT. The purpose of
the ICT was not to improve OS, but to reduce the tumor burden
to subclinical disease in patients with HPV+ OPC and to allow
in good responders the use of a reduced RT dose, 54Gy instead
of 70Gy, to eradicate the residual lower tumor burden (40, 41).
This lower RT dose to the tumor might lead to lower doses on
the surrounding normal tissue and subsequently to less treatment
related toxicity, such as dysphagia, feeding tube dependency,
and better post-treatment quality of life. Cisplatin, as concurrent
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TABLE 3 | De-intensification trials with reduced RT dose.
Name study Design Inclusion TNM 7th Inclusion TNM 8th Smoking Primary
endpoint
NCT01716195 One arm: ICT (2 cycli
paclitaxel-carboplatin) +
response adapted RT
(54Gy or 60Gy) with weekly
paclitaxel
T1T2-N2aN3;
T3T4-Nany
T1T2-N1N2 (excluding
N1 with only one
ipsilateral LN < 3 cm);
T3T4-Nany
/ 2Y PFS
NCT01530997 One arm: 60Gy + weekly
cisplatin
T0T3-N0N2c T1T3-N0N2 <10PY or
<30PY and abstinent
>5Y
Pathologic
Complete
Remission
NRG HN002
NCT02254278
Reduced 60Gy + weekly
cisplatin vs. 60Gy
T1T2-N1N2b;
T3-N0N2b
T1T2-N1;
T3-N0N1
<10 PY 2Y PFS
grade 3 dysphagia
ECOG 1308
NCT01084083
ICT (3 cycli of cisplatin,
paclitaxel, cetuximab), then
response adapted RT (54 or
69.3Gy) with cetuximab
Resectable disease
T3T4-N0; T1N1-T4N3
Resectable disease
T3T4-N0; T1N1-T4N3
/ 2Y PFS
The
Quarterback
Trial
NCT01706939
ICT (TPF), patients with
CR/PR randomized
between RT (56Gy) with
carboplatin vs. RT (70Gy)
with carboplatin
T3T4-N0; T1N1-T4N3
OPC/CUP/nasopharynx
T3T4-N0; T1N1-T4N3
OPC/CUP/nasopharynx
Exclusion of active
smokers or >20 PY
3Y PFS
ICT, induction chemotherapy; TPF, docetaxel, cisplatin, 5-fluorouracil; CR/PR, complete response / partial response; RT, radiotherapy; OPC, Oropharyngeal carcinoma; CUP, carcinoma
of unknown primary; PY, smoking pack years; 2Y, up to 2 years after end of treatment; PFS, progression free survival.
chemotherapy, was in this trial also replaced by cetuximab so the
same concerns about the efficacy of cetuximab in HPV+ OPC as
described above arise.
There is of course the concern that in patients who do not
have a complete response after ICT, ICT will not improve the
survival but will delay the start of the potentially curative RT
treatment of the radiosensitive HPV+ OPC. In another phase
II trial (NCT01716195) with dose adaptation after ICT, 2 cycles
of paclitaxel and carboplatin, complete or partial responders
received RT 54Gy with weekly paclitaxel, while less than partial
or no responders received RT 60Gy with weekly paclitaxel.
Although all patients in this trial received a lower RT dose than
the standard 70Gy, this treatment approach was associated with
a high 2y progression-free survival of 92% (42).
The results of the E1308 trial were published in 2017
showing a high rate of clinical complete response after ICT
(70%) with excellent 2y-OS of 94% and good toxicity profile
according to the authors. The published acute treatment related
toxicity is however worth mentioning, with 2 out of 80 patients
only receiving one out of 3 cycles of ICT due to grade 3
or more toxicity. Fourteen patients had dose adaptations of
cisplatin during ICT due to grade 3 or more hematologic
toxicity, neuropathy or tinnitus and 18 patients had dose
modification of cetuximab due to grade 3 or more acneiform
rash, mucositis or hypomagnesemia. It is debatable if the
reduction of RT dose and of the RT-related toxicity really
outweigh the added toxicity of ICT. ICT with TPF was associated
with 6.6% treatment-related toxicity in the recently published
GORTEC 2007-02 phase III trial randomizing HNSCC patients
between RT 70Gy with carboplatin-5FU vs. 3 cycles of TPF
followed by cetuximab-RT 70Gy (43). The Quarterback trial
(NCT01706939), another phase III dose reduction trial after ICT,
randomizes patients with good response after ICT between 56
and 70Gy concomitant with carboplatin. It should be noticed
that this trial also includes, besides HPV+ OPC, nasopharyngeal
cancers and cancers of unknown primary with p16+ squamous
cell carcinoma histology (Table 3). To our knowledge the
prognostic value of p16+ in HNSCC subsites other than OPC is
not proven and trials should therefore only include HPV+ OPC
patients to avoid bias and under-treatment of the other tumor
subsites.
CHANGES IN PRIMARY SURGERY ±
ADAPTIVE (C)RT
Surgery with or without adjuvant RT or CRT is an alternative
treatment strategy in HPV+ OPC if the anticipated functional
outcome after surgery is acceptable. Retrospective data have
shown similar oncologic outcome between open surgery and
radiotherapy. However, the rate of severe complications in
the surgery group was higher (44). It should be pointed out
that the surgical landscape has changed drastically since this
published comparison. Minimal invasive surgery such as the
transoral laser approach (TLM) or the transoral robotic surgery
(TORS), have gained prominence in the last decade. These
techniques, when performed by trained surgeons, provide similar
oncologic outcome as the classic approaches, while avoiding
mandibulotomy (45). As a result, they are associated with
fewer complications and functional deficits compared to the
classic approaches with mandibular split. To date, a prospective
randomized clinical trial concerning oncologic and functional
outcome of minimal invasive surgery vs. CRT has not yet been
published. Interestingly, two randomized ongoing trials, the
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“Best of” EORTC 1420 trial (NCT02984410) and the ORATOR
trial (NCT01590355), will compare the treatment related toxicity
of TORS and RT or CRT (46, 47).
The extent of benefit from adjuvant treatment after surgery
is based on the pathology following resection. Currently, it is
unclear if the decision for postoperative (C)RT and the RT
dose in HPV+ OPC must be based on the same pathology
features as in HPV– OPC. In HPV– OPC, ENE is considered
a negative prognostic factor and is now incorporated in the
most recent clinical and pathologic nodal staging classification
of TNM 8th Ed. In contrast, ENE was not adopted in the clinical
nor in the pathological TNM 8th edition for HPV+ OPC, even
though a recent analysis from the American national cancer data
base, including over 1,000 HPV+ OPC who underwent primary
surgery with negative resection margins, showed that ENE was
an independent risk factor for worse prognosis in patients with
HPV+ OPC. Surprisingly, adjuvant CRT compared with RT was
not associated with a better OS in this population (48).
At the moment, there are three de-intensification trials
trying to determine the optimal adjuvant treatment for HPV+
OPC after minimal invasive surgery. The ECOG 3311 trial
(NCT01898494) tries to determine the optimal RT dose by
dividing patients in three risk groups after TORS. The low-
risk group without adverse pathology features does not receive
adjuvant treatment. The intermediate risk group patients with
clear margins,<1mm ECE, 2-3 positive lymph nodes, perineural
invasion or lymphovascular invasion is randomized between RT
up to 50Gy or to 60Gy. The high risk group with positive
margins or >1mm ECE or ≥4 positive lymph nodes receive
standard CRT. The primary endpoint of this trial is 2-year
progression free survival. The PATHOS trial (NC02215265) will,
in addition, investigate the benefit of concomitant chemotherapy
in the high risk group. Patients with positive margins or ECE
are randomized between RT 60Gy with or without concomitant
chemotherapy. The ADEPT study (NCT01687413) only focuses
on the benefit of chemotherapy in patients with ECE and negative
margins and randomizes them between RT 60Gy with or without
concomitant chemotherapy.
OTHER EMERGING TREATMENT
STRATEGIES
Immunotherapy
Since the results of the CheckMate-141 study were published,
immunotherapy has become standard of care in recurrent
or metastatic HNSCC after platinum-based chemotherapy.
The OS benefit of nivolumab, a PD-1 monoclonal antibody,
was independent of p16 status, although the benefit was
more pronounced in the p16+ OPC (49). The Keynote-
012 study which investigated the efficacy of a similar PD-1
antibody, pembrolizumab, also observed a higher response to
pembrolizumab in patients with recurrent or metastatic HPV+
OPC vs. recurrent or metastatic HPV– HNSCC (50, 51). The
role of radiotherapy and the synergy with immunotherapy
TABLE 4 | Running trials with immunotherapy in human papillomavirus related oropharyngeal carcinoma.
Name study Design Inclusion TNM 7th Inclusion TNM 8th
(for p16+ OPC)
Smoking Primary
endpoint
RTOG 3504
NCT02764593
4 arms:
RT 70Gy + weekly cisplatin +
nivolumab
3-weekly cisplatin + nivolumab
cetuximab + nivolumab
nivolumab
OPC p16+:
T1T2-Nb2N3;
T4T3-N0N3,
OPC p16-;OC, Larynx,
HP:T1T2-N2aN3 or
T3T4-Nx
OPC p16+:
T1T2-N1N3 (excluding
N1 with only ipsilateral
LN); T3T4-Nx
OPC p16+: >10 PY or
<10 PY if T4 or N3
Dose limiting
toxicity (DLT)
Keynote-412
NCT03040999
RT 70Gy + 3-weekly cisplatin +
Pembrolizumab vs. placebo
All locally advanced
Head and neck
squamous cell
carcinoma’s;
independent of p16
status
All locally advanced
Head and neck
squamous cell
carcinoma’s;
independent of p16
status
/ 5Y-Event-free
survival
CA209-9TM
NCT03349710
Cisplatin eligible patient:
RT 70Gy + cisplatin +
nivolumab vs. placebo Cisplatin
ineligible patient:
RT 70Gy + Nivo vs. cetuximab
All locally advanced
OPC, OC, HP, or
larynx; independent of
p16 status
All locally advanced
OPC, OC, HP, or
larynx; independent of
p16 status
/ 6Y-Event-free
survival
CompARE
CRUK/13/026
4 arms:
RT 70Gy (OTT: 7 weeks) +
cisplatin
RT 64Gy (OTT: 5 weeks) +
3-weekly cisplatin
RT 70Gy (OTT: 7 weeks) +
3-weekly cisplatin + durvalumab
surgery + RT + cisplatin
OPC p16+:
T1T3-N2bN2c and all
T4 or N3
OPC p16–: T1T4-N1N3
or T3T4-N0
OPC p16+:
T1T3-N1N2 (excluding
N1 with only ipsilateral
LN); all T4 or N3
OPC p16+:
T1T3-N2bN2c only
included if more than
10 PY
Overall
survival
RT, radiotherapy; OPC, Oropharyngeal carcinoma; OC, oral cavity; HP, Hypopharynx; PY, smoking pack years; 5 (6)Y, up to 5 (6) years after end of treatment; OTT, Overall Treatment
Time; LN, lymph nodes.
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as adjuvant or concomitant treatment for advanced HPV +
OPC is still under investigation in several running phase I-
II [RTOG 3504 (NCT02764593)] and III trials [Keynote-412
(NCT03040999), CA209-9TM (NCT03349710), and CompARE
trial (CRUK/13/026)] (Table 4).
HPV+ OPC are believed to benefit more from
immunotherapy than HPV– OPC because of several factors.
First, HPV + tumors express viral antigens which can be
recognized as foreign by the patient’s immune system leading
to immune recognition and activation. Second, the preferred
tumor location of HPV+ OPC is situated in the tonsils or base
of tongue, two lymphoid tissues. This tumor location leads to the
presence of a higher level of CD8+ and PD-1 tumor infiltrating
lymphocytes and PDL-1 positive cells which may play a crucial
role in the better response of HPV+ OPC to immunotherapy
with PD-1 inhibitors such as nivolumab and pembrolizumab,
and to cetuximab, as described above (23, 52).
Proton Therapy
Decreased treatment related toxicity by the use of proton therapy
instead of photon therapy is still under investigation. The unique
energy transfer of proton therapy, with the highest energy
transfer at a specific depth inside the tissue, the Bragg peak,makes
it possible to spear more healthy tissue located posterior of the
tumor. A case matched analysis of 150 OPC, mainly HPV+,
treated with proton therapy or photon therapy was performed
showing comparable OS and PFS but reduced rate of feeding
tube dependency and severe weight loss in patients treated
with proton therapy (53). However, prospective multicenter
randomized trials, such as the ongoingNCT01893307, are needed
to validate such findings.
The proton RT technique is a quite expensive strategy and
probably not beneficial for all patients. Therefore, some have
proposed patient selection using a model based approach in
which a proton and photon treatment plan is made for each
patient and the expected reduction of toxicity with proton
therapy is calculated. If the toxicity reduction is more than a
pre-defined margin, the patient would undergo proton therapy
(54). In future, this treatment and selection strategy need to be
validated with incorporation of cost-effectiveness analysis as well
as patient-reported outcomes.
GENERAL CONCLUSION
In the next decade, the optimal treatment approach for HPV+
OPC will be determined based on the results of several running
trials. Sufficient follow up of all these studies is crucial in
order to be confident that outcome is not compromised, since
HPV+ disease shows a trend for later relapses than HPV–
disease. We must emphasize that until the mature results of
these trials are known the treatment of HPV+ OPC should
remain unchanged and identical to the treatment of HPV– OPC.
Furthermore, the result of the trials cannot be generalized to
all HPV+ OPC. As described above, most trials have different
inclusion criteria in terms of TNM stage and smoking pack
years. In addition, there is no consensus on HPV detection
method. Whether the future treatment for HPV+ OPC will
consist of changes in concomitant therapy, reduction of RT
dose, immunotherapy or proton therapy, patient selection will be
pivotal.
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